MARKET

TERN

TERN

Terns Pharmaceuticals, Inc.
NASDAQ
44.29
+1.47
+3.43%
Pre Market: 44.20 -0.09 -0.20% 08:38 03/10 EDT
OPEN
42.54
PREV CLOSE
42.82
HIGH
44.38
LOW
41.70
VOLUME
386
TURNOVER
0
52 WEEK HIGH
48.26
52 WEEK LOW
1.865
MARKET CAP
4.82B
P/E (TTM)
-42.9250
1D
5D
1M
3M
1Y
5Y
1D
Terns Pharmaceuticals publishes corporate presentation on TERN-701 oral allosteric BCR-ABL inhibitor for CML with 75% MMR at 24 weeks
Reuters · 16h ago
Weekly Report: what happened at TERN last week (0302-0306)?
Weekly Report · 1d ago
Investment Firm Builds Position in TERN Stock, According to Recent SEC Filing
The Motley Fool · 4d ago
Weekly Report: what happened at TERN last week (0223-0227)?
Weekly Report · 03/02 09:43
Does Rising Hedge Fund Interest in Terns (TERN) Reveal a Deeper Bet on Single-Asset Biotech Risk?
Simply Wall St · 02/28 16:31
Terns Pharmaceuticals (TERN) Valuation Check After Strong Recent Share Price Run And CML Narrative Shift
Simply Wall St · 02/27 11:38
Terns Pharmaceuticals to Join TD Cowen, Leerink, Barclays, and Citizens Investor Conferences in March
Reuters · 02/25 21:06
Commit To Buy Terns Pharmaceuticals At $30, Earn 34% Using Options
NASDAQ · 02/23 17:29
More
About TERN
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its product candidates in pipeline includes TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic dysfunction-associated steatohepatitis (MASH). It is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.

Webull offers Terns Pharmaceuticals Inc stock information, including NASDAQ: TERN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TERN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TERN stock methods without spending real money on the virtual paper trading platform.